/
CNTB
$2.38+$0.19 (+8.68%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$137.9M
63M shares
52-week range
$0.98 – $3.82
49% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
1.44%
Moderate
Price (6 mo)
Loading chart…
Change$-17.42
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $26.0M | $64.0K |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $26.0M | $64.0K |
| Gross margin | — | — | — | — | — | 100.0% | 100.0% |
| R&D | $15.4M | $23.1M | $80.5M | $96.6M | $53.0M | $29.3M | $37.8M |
| Operating income | −$16.0M | −$30.3M | −$98.1M | −$119.3M | −$69.1M | −$22.5M | −$58.1M |
| EBITDA | −$24.8M | −$118.2M | −$201.4M | −$116.7M | −$61.3M | −$14.7M | −$54.6M |
| Net income | −$24.5M | −$119.4M | −$202.3M | −$118.1M | −$62.1M | −$15.6M | −$55.5M |
| Net margin | — | — | — | — | — | -60.0% | -86687.5% |
| EPS (diluted) | -3.02 | -14.45 | -25.00 | -14.50 | -1.08 | -0.28 | -1.00 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $5M | $-1.06 | $-1.21–$-0.79 | 4 |
| 2027 | $9M | $-1.07 | $-1.38–$-0.75 | 5 |
| 2028 | $17M | $-0.95 | $-1.13–$-0.59 | 4 |
| 2029 | $35M | $-0.77 | $-2.21–$0.18 | 2 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.66
Price
$2.38
Implied downside
-72%
Peer comparison
Connect Biopharma Holdings Limited Ordinary Shares
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
www.connectbiopharm.com- Employees
- 64
- IPO / List date
- Sep 3, 2025
- HQ
- SAN DIEGO, CA
Held by traders on TradeandTell
No one on the platform currently holds CNTB.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in CNTB as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded CNTB yet.
